[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT939648E - Formulações de vacinas de rotavírus - Google Patents

Formulações de vacinas de rotavírus Download PDF

Info

Publication number
PT939648E
PT939648E PT97944477T PT97944477T PT939648E PT 939648 E PT939648 E PT 939648E PT 97944477 T PT97944477 T PT 97944477T PT 97944477 T PT97944477 T PT 97944477T PT 939648 E PT939648 E PT 939648E
Authority
PT
Portugal
Prior art keywords
vaccine formulations
rotavirus vaccine
rotavirus
formulations
vaccines
Prior art date
Application number
PT97944477T
Other languages
English (en)
Inventor
Carl J Burke
David B Volkin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621991.0A external-priority patent/GB9621991D0/en
Priority claimed from GBGB9714333.3A external-priority patent/GB9714333D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PT939648E publication Critical patent/PT939648E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT97944477T 1996-09-26 1997-09-26 Formulações de vacinas de rotavírus PT939648E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2675496P 1996-09-26 1996-09-26
GBGB9621991.0A GB9621991D0 (en) 1996-10-22 1996-10-22 Rotavirus vaccine formulations
US4676097P 1997-05-16 1997-05-16
GBGB9714333.3A GB9714333D0 (en) 1997-07-07 1997-07-07 Rotavirus vaccine formulations

Publications (1)

Publication Number Publication Date
PT939648E true PT939648E (pt) 2008-01-11

Family

ID=27451542

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97944477T PT939648E (pt) 1996-09-26 1997-09-26 Formulações de vacinas de rotavírus

Country Status (10)

Country Link
EP (2) EP1891968A3 (pt)
JP (1) JP4653262B2 (pt)
AT (1) ATE377428T1 (pt)
AU (1) AU739916B2 (pt)
CA (1) CA2266486C (pt)
DE (1) DE69738271T2 (pt)
DK (1) DK0939648T3 (pt)
ES (1) ES2294801T3 (pt)
PT (1) PT939648E (pt)
WO (1) WO1998013065A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
US6436993B1 (en) 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
ES2260046T3 (es) * 1999-08-17 2006-11-01 Glaxosmithkline Biologicals S.A. Procedimiento para separar variantes rotavirus y vacuna de rotavirus vivos atenuados.
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2008231072B2 (en) * 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
AU2013224715B2 (en) * 2007-03-22 2015-10-08 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
KR102023207B1 (ko) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 동결건조 바이러스 제형
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
AU2012272788B2 (en) 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
EP2747777A4 (en) * 2011-08-25 2015-04-29 Brian Pulliam ROTAVIRUS PREPARATIONS WITH EXCESSIVE CALCIUMIONES AND HIGH VISCOSITY TO ENSURE VACCINITY OF THE VACCINE AT HIGH TEMPERATURES
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
BR112017000515A2 (pt) * 2014-07-18 2017-11-14 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd formulação de vacina contra rotavírus termoestável seca por liofilização e processo para preparação da mesma
RU2018126322A (ru) 2015-12-18 2020-01-20 Мерк Шарп И Доум Корп. Термически стабильные ротавирусные вакцинные композиции и способы их применения
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
EP4010016A1 (en) * 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine
EP4010015A1 (en) * 2019-08-09 2022-06-15 Valneva SE Chikungunya vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
DK0493575T3 (da) * 1990-07-26 1999-06-14 Wistar Inst Vaccine af reassortant rotavirus
US7150984B2 (en) * 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine

Also Published As

Publication number Publication date
JP4653262B2 (ja) 2011-03-16
AU739916B2 (en) 2001-10-25
EP1891968A2 (en) 2008-02-27
DK0939648T3 (da) 2008-02-11
DE69738271D1 (de) 2007-12-20
DE69738271T2 (de) 2008-08-28
ATE377428T1 (de) 2007-11-15
ES2294801T3 (es) 2008-04-01
WO1998013065A1 (en) 1998-04-02
CA2266486C (en) 2007-09-25
EP1891968A3 (en) 2008-09-03
CA2266486A1 (en) 1998-04-02
AU4596397A (en) 1998-04-17
EP0939648B1 (en) 2007-11-07
JP2002500622A (ja) 2002-01-08
EP0939648A1 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
PT939648E (pt) Formulações de vacinas de rotavírus
IL190554A0 (en) Papilloma virus capsomere vaccine formulations and methods of use
TW289050B (pt)
FI931169A7 (fi) Parannetut rokotekoostumukset
HUP9903713A3 (en) Stabilisers for live vaccines
HU9601466D0 (en) Adjuvants for viral vaccines
DK1047446T3 (da) Vaccinesammensætning til Herpes Simplex virus og fremgangsmåder til anvendelser deraf
HU9601462D0 (en) Adjuvants for viral vaccines
GB2301591A (en) Cytotoxic T-cell epitopes
EP0533804A4 (en) Sigma binding site agents
PT792165E (pt) Composicoes imunogenicas
AU3125795A (en) Attenuated human rotavirus vaccine
HU9600207D0 (en) Vaccine compositions
HUP9701586A3 (en) Improved inactivated vaccines
AU3474593A (en) Hypericin treatment of vaccine agents for improved immunogenicity
AU3755999A (en) Proteins that direct the secretion of virulence proteins and vaccines comprisingthem
GB9615022D0 (en) Vaccine preparations
EP0516287A3 (en) Human rotavirus hcr3, reassortants thereof and vaccine compositions containing them
GB9614618D0 (en) Vaccine compositions
GB9621991D0 (en) Rotavirus vaccine formulations
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
GB9213882D0 (en) Live modified equine herpesvirus-4 vaccine
MX9705959A (es) Formulaciones para il-12.
ZA965334B (en) Controlled release formulations of ranitidine
AUPM370894A0 (en) Improved adjuvant for vaccines